Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
My previous session
Most popular
  Report  
Real-time Quote. Real-time CHI-X - 01/18 11:30:00 am
5577 GBp   +1.22%
2018Moderna Declines in Market Debut -- WSJ
DJ
2018Glaxo Makes Big Cancer-Drug Bet -- WSJ
DJ
2018GlaxoSmithKline to Acquire Tesaro for $4.16 Billion -- Update
DJ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/14/2019 01/15/2019 01/16/2019 01/17/2019 01/18/2019 Date
5509(c) 5557(c) 5496(c) 5510(c) 5570 Last
4 052 678 3 143 938 3 842 704 2 706 165 2 974 052 Volume
-3.55% +0.87% -1.10% +0.25% +1.09% Change
More quotes
Financials (USD)
Sales 2018 22 068 M
EBIT 2018 5 636 M
Net income 2018 2 355 M
Debt 2018 14 332 M
Yield 2018 3,79%
Sales 2019 23 496 M
EBIT 2019 6 187 M
Net income 2019 2 743 M
Debt 2019 15 034 M
Yield 2019 3,84%
P/E ratio 2018 38,20
P/E ratio 2019 33,15
EV / Sales2018 4,72x
EV / Sales2019 4,47x
Capitalization 89 927 M
More Financials
Company
AstraZeneca is one of the world's leading pharmaceutical groups. Net sales break down by treatment area as follows: - cardiovascular and metabolic diseases (32.3%); - respiratory diseases (20.9%); - oncology (17.9%); - other (18.5%): inflammatory and autoimmune diseases, neurological diseases,... 
Sector
Pharmaceuticals
Calendar
02/14Earnings Release
More about the company
Surperformance© ratings of AstraZeneca
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTRAZENECA
02:09aASTRAZENECA : Linzess (linaclotide) approved in China for the treatment of irrit..
PU
01/17Phoenix, Roche partner to develop TNBC biomarker
AQ
01/16MANAGEMENT TRACKS : Immunocore gains second ex-AZ exec
AQ
01/15European nations weigh impact of Brexit on drug supplies
RE
01/15MSKCC says senior execs may not hold industry board seats
AQ
01/14GLOBAL MARKETS LIVE : PG&E, Newmont, Nissan, Amazon…
01/14ASTRAZENECA : Chief Medical Officer Sean Bohen to Resign
DJ
01/14ASTRAZENECA : Chief Medical Officer to Leave Amid Restructuring -Bloomberg
DJ
01/11LONDON STOCK EXCHANGE : FTSE dips as sterling firms on report of potential Brexi..
RE
01/08SOSEI : Heptares to Receive US$15 Million Milestone Payment From AstraZeneca Wit..
AQ
More news
Analyst Recommendations on ASTRAZENECA
More recommendations
Sector news : Pharmaceuticals - NEC
08:06aAT&T ads returning to YouTube, two years after pulling back over content
RE
07:55aELI LILLY AND : Sarcoma Drug Combo Proves Ineffective in Trials
DJ
06:56aSUN PHARMACEUTICAL INDUSTRIES : India's Sun Pharma asks regulator to examine med..
RE
05:01aSUN PHARMACEUTICAL INDUSTRIES : India's Sun Pharma tumbles on reports of fresh w..
RE
01/17JOHNSON & JOHNSON : to Use Apple Watch App for Heart-Health Study -- Update
DJ
More sector news : Pharmaceuticals - NEC
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 80,4 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA-6.18%89 927
JOHNSON & JOHNSON-0.78%346 217
PFIZER-3.53%246 326
NOVARTIS4.74%226 774
ROCHE HOLDING LTD.5.65%223 350
MERCK AND COMPANY-1.06%196 588